NCT07023666RecruitingPhase 2
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Early Detection and Management of Cardiac Iron Overload in Sickle Cell Disease Using Multimodal Imaging for Improved Clinical Outcomes
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 9 Jun 2025
- Start date
- 7 Oct 2025
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Inova Health Care Services
- Diseases
- Sickle cell disease
- NCT number
- NCT07023666
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From 7 Oct 2025 to the primary completion date, 30 Jun 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known heart failure
- Unstable angina
- Active infection or severe comorbid conditions that in the view of the investigator would limit participation
- History of hypersensitivity or contraindication to chelation therapy
- Severe renal or hepatic impairment
Other
- Unable to schedule and required follow-up visits
- Medical comorbidities including:
- Uncontrolled dysrhythmias
- Acute pulmonary embolism
- Pregnancy of breastfeeding
Who the study is looking for
- At least 18 years of age
- Diagnosis of sickle cell disease (any genotype)
- Serum ferritin levels ≥ 400 ng/mL (up to 80 patients), or less than 400 ng/mL in those who have cardiac symptoms including shortness of breath and lower extremity edema (up to 20 patients)
- Willingness to undergo regular imaging (echocardiograms, ECG, cardiac MRI)
- ECOG performance status of 0-1
- Able to read, understand and provide written informed consent
- Deemed appropriate for participation by the treating physician
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Inova Schar Cancer Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
| Inova Health Care Service Coordinator of this site? Confirm its status | Falls Church | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.